中国全科医学 ›› 2019, Vol. 22 ›› Issue (17): 2099-2105.DOI: 10.12114/j.issn.1007-9572.2019.00.041
朱悦,孙耕耘*
出版日期:
2019-06-15
发布日期:
2019-06-15
基金资助:
ZHU Yue,SUN Gengyun*
Published:
2019-06-15
Online:
2019-06-15
摘要: 近年来,免疫检查点抑制剂(ICB)在晚期非小细胞肺癌(NSCLC)的治疗中进展非常迅速,也是目前最热门的肿瘤治疗手段之一。尤其是对于驱动基因突变阴性的患者,在最新的美国国立综合癌症网络(NCCN)指南中甚至提到了一线治疗的地位。前不久国家食品药品监督管理总局(CFDA)对于ICB的批准给肿瘤治疗带来了全新的治疗理念,为肺癌患者带来了新的希望,ICB具有广阔的临床应用前景。但是,临床上仍存在许多问题有待解决,如基线使用类固醇激素是否影响ICB疗效,抗生素的累积使用对ICB疗效如何,脑转移人群ICB疗效是否不佳,ICB结合局部脑照射是否获益,烟草暴露状态是否影响免疫应答,随着这些问题的相继解决,抗程序性死亡分子1(PD-1)/PD-1配体(PD-L1)单抗将会使更多特殊人群在生存上获益。
[1]SIEGEL R L,MILLER K D,JEMAL A,et al.Cancer statistics[J].CA Cancer J Clin,2017,67(1):7-30.DOI:10.3322/caac.21387. [2]MALVEZZI M,CARIOLI G,BERTUCCIO P,et al.European cancer mortality predictions for the year 2016 with focus on leukaemias[J].Ann Oncol,2016,27(4):725-731.DOI:10.1093/annonc/mdw022. [3]黄志煜,李晖,范云.抗PD-1/PD-L1单抗治疗肺癌临床研究进展[J].中国肺癌杂志,2015,18(11):706-713.DOI:10.3779/j.issn.1009-3419.2015.11.09. HUANG Z Y,LI H,FAN Y.Clinical research progress of anti PD-1/PD-L1 monoclonal antibody in the treatment of lung cancer[J].Chinese Journal of Lung Cancer,2015,18(11):706-713.DOI:10.3779/j.issn.1009-3419.2015.11.09. [4]曾玉兰,刘洋洋,梁金燕,等.免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J].实用肿瘤学杂志,2017,31(4):353-358.DOI:10.11904/j.issn.1002-3070.2017.04.012. ZENG Y L,LIU Y Y,LIANG J Y,et al.Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy[J].Practical Oncology Journal,2017,31(4):353-358.DOI:10.11904/j.issn.1002-3070.2017.04.012. [5]GETTINGER S,HORN L,JACKMAN D,et al.Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J].J Clin Oncol,2018,36(17):1675-1684.DOI:10.1200/JCO.2017.77.0412. [6]CRITTENDEN M R,ZEBERTAVAGE L,KRAMER G,et al.Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity[J].Sci Rep,2018,8(1):7012.DOI:10.1038/s41598-018-25482-w. [7]WEHLER T,THOMAS M,SCHUMANN C,et al.A randomized,phase 2 evaluation of the CHK1 inhibitor,LY2603618,administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer[J].Lung Cancer,2017,108:212-216.DOI:10.1016/j.lungcan.2017.03.001. [8]TABCHI S,KOURIE H R,KATTAN J.Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer:a new therapeutic strategy[J].Invest New Drugs,2016,34(6):794-796.DOI:10.1007/s10637-016-0383-2. [9]HELWICK C.Experts consider the new immunotherapy paradigm in advanced lung cancer[C].American:ASCO Annual Meeting,2016. [10]ARBOUR K C,MEZQUITA L,LONG N,et al.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer[J].J Clin Oncol,2018,36(28):2872-2878.DOI:10.1200/JCO.2018.79.0006. [11]RYKEN T C,MCDERMOTT M,ROBINSON P D,et al.The role of steroids in the management of brain metastases:a systematic review and evidence-based clinical practice guideline[J].J Neurooncol,2010,96(1):103-114.DOI:10.1007/s11060-009-0057-4. [12]PAULSEN O,KLEPSTAD P,ROSLAND J H,et al.Efficacy of methylprednisolone on pain,fatigue,and appetite loss in patients with advanced cancer using opioids:a randomized,placebo-controlled,double-blind trial[J].J Clin Oncol,2014,32(29):3221-3228.DOI:10.1200/JCO.2013.54.3926. [13]YENNURAJALINGAM S,FRISBEE-HUME S,PALMER J L,et al.Reduction of cancer-related fatigue with dexamethasone:a double-blind,randomized,placebo-controlled trial in patients with advanced cancer[J].J Clin Oncol,2013,31(25):3076-3082.DOI:10.1200/JCO.2012.44.4661. [14]BEN-AHARON I,GAFTER-GVILI A,LEIBOVICI L,et al.Interventions for alleviating cancer-related dyspnea:a systematic review and meta-analysis[J].Acta Oncol,2012,51(8):996-1008.DOI:10.3109/0284186X.2012.709638. [15]LIN R J,ADELMAN R D,MEHTA S S.Dyspnea in palliative care:expanding the role of corticosteroids[J].J Palliat Med,2012,15(7):834-837.DOI:10.1089/jpm.2011.0260. [16]LIBERT C,DEJAGER L.How steroids steer T cells[J].Cell Rep,2014,7(4):938-939.DOI:10.1016/j.celrep.2014.04.041. [17]BIANCHI M,MENG C,IVASHKIV L B.Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids[J].Proc Natl Acad Sci USA,2000,97(17):9573-9578.DOI:10.1073/pnas.160099797. [18]CHEN X,MURAKAMI T,OPPENHEIM J J,et al.Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death[J].Eur J Immunol,2004,34(3):859-869.DOI:10.1002/eji.200324506. [19]CHEN X,OPPENHEIM J J,WINKLER-PICKETT R T,et al.Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE[J].Eur J Immunol,2006,36(8):2139-2149.DOI:10.1002/eji.200635873. [20]IM S J,HASHIMOTO M,GERNER M Y,et al.Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy[J].Nature,2016,537(7620):417-421.DOI:10.1038/nature19330. [21]VETIZOU M,PITT J M,DAILLERE R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J].Science,2015,350(6264):1079-1084.DOI:10.1126/science.aad1329. [22]SIVAN A,CORRALES L,HUBERT N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science,2015,350(6264):1084-1089.DOI:10.1126/science.aac4255. [23]SCHELENZ S,GILES D,ABDALLAH S.Epidemiology,management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre[J].Ann Oncol,2012,23(7):1889-1893.DOI:10.1093/annonc/mdr520. [24]JERNBERG C,LOFMARK S,EDLUND C,et al.Long-term impacts of antibiotic exposure on the human intestinal microbiota[J].Microbiology,2010,156(Pt 11):3216-3223.DOI:10.1099/mic.0.040618-0. [25]LANGE K,BUERGER M,STALLMACH A,et al.Effects of antibiotics on gut microbiota[J].Dig Dis,2016,34(3):260-268.DOI:10.1159/000443360. [26]JAKOBSSON H E,JERNBERG C,ANDERSSON A F,et al.Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome[J].PLoS One,2010,5(3):e9836.DOI:10.1371/journal.pone.0009836. [27]CECILIA ARBOUR K.Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC[C].America:ASCO Annual Meeting,2018. [28]PAVLAKIS N.Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso,a study of nintedanib (N) vs.placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM)[C].America:ASCO Annual Meeting,2018. [29]DEROSA L,HELLMANN M D,SPAZIANO M,et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J].Ann Oncol,2018,29(6):1437-1444.DOI:10.1093/annonc/mdy103. [30]AHMED J,KUMAR A,PARIKH K,et al.Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors[J].Oncoimmunology,2018,7(11):e1507670.DOI:10.1080/2162402X.2018.1507670. [31]HUEMER F,RINNERTHALER G,WESTPHAL T,et al.Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer[J].Oncotarget,2018,9(23):16512-16520.DOI:10.18632/oncotarget.24751. [32]ARVOLD N D,LEE E Q,MEHTA M P,et al.Updates in the management of brain metastases[J].Neuro Oncol,2016,18(8):1043-1065.DOI:10.1093/neuonc/now127. [33]NAYAK L,LEE E Q,WEN P Y.Epidemiology of brain metastases[J].Curr Oncol Rep,2012,14(1):48-54.DOI:10.1007/s11912-011-0203-y. [34]KHASRAW M,POSNER J B.Neurological complications of systemic cancer[J].Lancet Neurol,2010,9(12):1214-1227.DOI:10.1016/S1474-4422(10)70220-9. [35]YANG H,LU S Q.Advances and strategy of up-to-date treatment of brain metastases[J].Biomed Research International,2010,2014(1):93-100.DOI:10.1155/2014/484161. [36]AMELOT A,TERRIER L M,MATHON B,et al.Can anticancer chemotherapy promote the progression of brain metastases?[J].Med Oncol,2018,35(3):35.DOI:10.1007/s12032-018-1097-4. [37]AKAMATSU H,KATAKAMI N,OKAMOTO I,et al.Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer:AURA3 trial[J].Cancer Sci,2018,109(6):1930-1938.DOI:10.1111/cas.13623. [38]VANSTEENKISTE J,REUNGWETWATTANA T,NAKAGAWA K,et al.CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC):data from the FLAURA study[J].Ann Oncol,2017,28(suppl 10):x7.DOI:10.1093/annonc/mdx782. [39]WEBER J S,AMIN A,MINOR D,et al.Safety and clinical activity of ipilimumab in melanoma patients with brain metastases:retrospective analysis of data from a phase 2 trial[J].Melanoma Res,2011,21(6):530-534.DOI:10.1097/CMR.0b013e32834d3d88. [40]LONG G V,ATKINSON V,LO S,et al.Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases:a multicentre randomised phase 2 study[J].Lancet Oncol,2018,19(5):672-681.DOI:10.1016/S1470-2045(18)30139-6. [41]BORDONI R,CIARDIELLO F,VON PAWEL J,et al.Patient-reported outcomes in OAK:a phase Ⅲ study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer[J].Clin Lung Cancer,2018,19(5):441-449.e4.DOI:10.1016/j.cllc.2018.05.011. [42]BARLESI F,STEINS M,HORN L,et al.Long-term outcomes with nivolumab vs docetaxel in patients with advanced NSCLC:CheckMate 017 and CheckMate 057 2-y update[C].Denmark:Esmo Congress,2016. [43]RIZVI N A,MAZIERES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.DOI:10.1016/S1470-2045(15)70054-9. [44]KAMATH S D,KUMTHEKAR P U.Immune checkpoint inhibitors for the treatment of entral nervous system (CNS) metastatic disease[J].Front Oncol,2018,8:414.DOI:10.3389/fonc.2018.00414. [45]GIANNONI P,BADAUT J,DARGAZANLI C,et al.The pericyte-glia interface at the blood-brain barrier[J].Clin Sci,2018,132(3):361-374.DOI:10.1042/CS20171634. [46]PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.DOI:10.1038/nrc3239. [47]BRASTIANOS P K,CARTER S L,SANTAGATA S,et al.Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets[J].Cancer Discov,2015,5(11):1164-1177.DOI:10.1158/2159-8290.CD-15-0369. [48]FIDLER I J.The biology of brain metastasis:challenges for therapy[J].Cancer J,2015,21(4):284-293.DOI:10.1097/PPO.0000000000000126. [49]HENDRIKS L.Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)[C].America:ASCO Annual Meeting,2018. [50]DALY M E,MONJAZEB A M,KELLY K.Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer[J].J Thorac Oncol,2015,10(12):1685-1693.DOI:10.1097/JTO.0000000000000686. [51]REYNDERS K,ILLIDGE T,SIVA S,et al.The abscopal effect of local radiotherapy:using immunotherapy to make a rare event clinically relevant[J].Cancer Treat Rev,2015,41(6):503-510.DOI:10.1016/j.ctrv.2015.03.011. [52]DENG L,LIANG H,BURNETTE B,et al.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J].J Clin Invest,2014,124(2):687-695.DOI:10.1172/JCI67313. [53]VATNER R E,COOPER B T,VANPOUILLE-BOX C,et al.Combinations of immunotherapy and radiation in cancer therapy[J].Front Oncol,2014,4:325.DOI:10.3389/fonc.2014.00325. [54]TOMASINI P,GREILLIER L,BOYER A,et al.Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer[J].J Thorac Dis,2018,10(Suppl 9):S1032-1036.DOI:10.21037/jtd.2018.04.61. [55]KIRKPATRICK J P,KELSEY C R,PALTA M,et al.Stereotactic body radiotherapy:a critical review for nonradiation oncologists[J].Cancer,2014,120(7):942-954.DOI:10.1002/cncr.28515. [56]SCHAUE D,RATIKAN J A,IWAMOTO K S,et al.Maximizing tumor immunity with fractionated radiation[J].Int J Radiat Oncol Biol Phys,2012,83(4):1306-1310.DOI:10.1016/j.ijrobp.2011.09.049. [57]LEE Y,AUH S L,WANG Y,et al.Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.DOI:10.1182/blood-2009-02-206870. [58]CHEN D S,MELLMAN I.Elements of cancer immunity and the cancer-immune set point[J].Nature,2017,541(7637):321-330.DOI:10.1038/nature21349. [59]LUKE J J,LEMONS J M,KARRISON T G,et al.Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J].J Clin Oncol,2018,36(16):1611-1618.DOI:10.1200/JCO.2017.76.2229. [60]KLUG F,PRAKASH H,HUBER P E,et al.Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy[J].Cancer Cell,2013,24(5):589-602.DOI:10.1016/j.ccr.2013.09.014. [61]DEMARIA S,FORMENTI S C.Radiation as an immunological adjuvant:current evidence on dose and fractionation[J].Front Oncol,2012,2:153.DOI:10.3389/fonc.2012.00153. [62]Cancer Genome Atlas Research Network.Comprehensive genomic characterization of squamous cell lung cancers[J].Nature,2012,489(7417):519-525.DOI:10.1038/nature11404. [63]BRAHMER J,RECKAMP K L,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.DOI:10.1056/NEJMoa1504627. [64]GAINOR J F.Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression[C].America:ASCO Annual Meeting,2018. [65]CHAMPIAT S,FERTE C,LEBEL-BINAY S,et al.Exomics and immunogenics:bridging mutational load and immune checkpoints efficacy[J].Oncoimmunology,2014,3(1):e27817.DOI:10.4161/onci.27817. [66]RIZVI N A,HELLMANN M D,SNYDER A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128.DOI:10.1126/science.aaa1348. [67]INAMURA K,YOKOUCHI Y,KOBAYASHI M,et al.WITHDRAWN:tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis[J].Lung Cancer,2016,243(1):21-28.DOI:10.1016/j.lungcan.2016.09.016. [68]LAWRENCE M S,STOJANOV P,POLAK P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.DOI:10.1038/nature12213. [69]GOVINDAN R,DING L,GRIFFITH M,et al.Genomic landscape of non-small cell lung cancer in smokers and never-smokers[J].Cell,2012,150(6):1121-1134.DOI:10.1016/j.cell.2012.08.024. [70]TAKADA K,TOYOKAWA G,OKAMOTO T,et al.A comprehensive analysis of programmed cell death ligand-1 expression with the clone SP142 antibody in non-small-cell lung cancer patients[J].Clin Lung Cancer,2017,18(5):572-582.e1.DOI:10.1016/j.cllc.2017.02.004. [71]LAWRENCE M S,STOJANOV P,POLAK P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.DOI:10.1038/nature12213. [72]SNYDER A,MAKAROV V,MERGHOUB T,et al.Genetic basis for clinical response to CTLA-4 blockade in melanoma[J].N Engl J Med,2014,371(23):2189-2199.DOI:10.1056/NEJMoa1406498. [73]ROONEY M S,SHUKLA S A,WU C J,et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity[J].Cell,2015,160(1/2):48-61.DOI:10.1016/j.cell.2014.12.033. [74]STRICKLAND K C,HOWITT B E,SHUKLA S A,et al.Association and prognostic significance of BRCA1/2-mutation status with neoantigen load,number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer[J].Oncotarget,2016,7(12):13587-13598.DOI:10.18632/oncotarget.7277. [75]GIBBONS D L,BYERS L A,KURIE J M.Smoking,p53 mutation,and lung cancer[J].Mol Cancer Res,2014,12:3-13.DOI:10.1158/1541-7786.MCR-13-0539. [76]RIZVI H,SANCHEZ-VEGA F,LA K,et al.Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J].J Clin Oncol,2018,36(7):633-641.DOI:10.1200/JCO.2017.75.3384. [77]HELLMANN M D,CIULEANU T E,PLUZANSKI A,et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.DOI:10.1056/NEJMoa1801946. [78]WU Y L,LU S,CHENG Y,et al.Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC):results of the phase 3 CheckMate 078 study[J].Cancer Res,2018,78(13):14-18.DOI:10.1158/1538-7445. |
[1] | 朱文鹏, 韩梦琦, 王雨欣, 王国平. 1990—2019年中国鼻咽癌发病与死亡的趋势及预测研究[J]. 中国全科医学, 2023, 26(34): 4269-4276. |
[2] | 张继方, 陈芳, 唐佳雯, 李红亮. 肿瘤出芽及肿瘤浸润淋巴细胞对食管鳞状细胞癌淋巴结转移的预测价值研究[J]. 中国全科医学, 2023, 26(32): 4038-4042. |
[3] | 张懂理, 沈冲, 张卫川, 陈海滨, 赵建军. 程序性死亡因子1/程序性死亡因子1配体抑制剂治疗肾细胞癌有效性及安全性的Meta分析[J]. 中国全科医学, 2023, 26(30): 3815-3822. |
[4] | 李吉磊, 李洪霖, 许彦超, 刘亚南, 陈梦利, 邵帅, 马纯政. 消痰化瘀通噎颗粒配合通道开结丸联合化疗治疗食管癌的临床疗效研究[J]. 中国全科医学, 2023, 26(30): 3759-3764. |
[5] | 郑玉玲, 张亚玲, 刘怀民, 许彦超, 贾晓琳, 李军赛, 贺文龙, 仝新朵, 秦善文, 张丽涵. 丁香管食通含化丸单用及联合附桂管食通颗粒治疗晚期食管癌的临床研究[J]. 中国全科医学, 2023, 26(30): 3765-3771. |
[6] | 闫可, 魏菀怡, 李曙光, 么伟楠, 董静, 王晓斌, 张雪原, 杨洁, 沈文斌, 祝淑钗. 巩固化疗对接受根治性同步放化疗的临床Ⅱ~Ⅲ期食管鳞状细胞癌患者预后的影响分析[J]. 中国全科医学, 2023, 26(30): 3772-3779. |
[7] | 闫可, 魏菀怡, 邓文钊, 沈文斌, 李曙光, 杜星语, 张雪原, 杨洁, 祝淑钗. 颈胸上段食管鳞癌根治性同步放化疗远期预后分析及影响因素研究[J]. 中国全科医学, 2023, 26(30): 3785-3790. |
[8] | 陈伦文, 周阳, 闫国栋, 沈怡, 孙晨, 蔡婉丽, 褚敏捷, 肖静. 2型糖尿病的恶性肿瘤风险:一项基于人群的前瞻性研究[J]. 中国全科医学, 2023, 26(26): 3238-3245. |
[9] | 段玉霞, 李珍, 张斯齐, 房志学, 秦月兰. 结直肠癌诊疗中患者决策辅助工具应用效果的系统评价[J]. 中国全科医学, 2023, 26(25): 3194-3201. |
[10] | 嵇梦颖, 李雨荆, 陈醒, 戴辉华, 孙莹. B超联合肿瘤标志物对卵巢黏液性肿瘤恶变的预测价值研究[J]. 中国全科医学, 2023, 26(24): 3022-3027. |
[11] | 王瑞, 王小梅, 彭国庆, 余欢, 王思涵, 夏瑾. 成人癌症恶病质的筛查评估与干预治疗——基于《成人癌症恶病质:ESMO临床实践指南》解读[J]. 中国全科医学, 2023, 26(23): 2823-2829. |
[12] | 赵泽玮, 康宁, 郭丰丽, 王钟玉, 郑向前. 极光激酶A表达对甲状腺髓样癌切除术后患者生化治愈的影响作用研究[J]. 中国全科医学, 2023, 26(20): 2508-2512. |
[13] | 张玉双, 孔令洋, 管佳畅, 李建波, 王一然, 王瑜, 李晶. 基于16S rDNA测序探索食管鳞状细胞癌患者肠道菌群特征[J]. 中国全科医学, 2023, 26(20): 2496-2502. |
[14] | 陈璐璐, 张利苹, 李静文, 董文杰, 吴欣爱. 程序性死亡受体1抑制剂联合呋喹替尼后线治疗转移性结直肠癌的临床疗效和安全性研究[J]. 中国全科医学, 2023, 26(18): 2262-2267. |
[15] | 沈傲梅, 路潜, 符鑫, 韦小夏, 卞静如, 张丽媛, 强万敏, 庞冬. 基于前瞻性队列研究的Meta分析构建乳腺癌相关淋巴水肿风险预测模型研究[J]. 中国全科医学, 2023, 26(17): 2078-2088. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||